- Home
- MLTX vs XERS Comparison
MLTX vs XERS Comparison
Compare MLTX & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MLTX | XERS |
|---|---|---|
| Founded | 2021 | 2005 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MLTX | XERS |
|---|---|---|
| Price | $16.81 | $6.02 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 6 |
| Target Price | ★ $27.50 | $10.83 |
| AVG Volume (30 Days) | 1.3M | ★ 1.4M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 100.00 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $49,590,000.00 |
| Revenue This Year | N/A | $34.37 |
| Revenue Next Year | N/A | $22.86 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 142.67 |
| 52 Week Low | $5.95 | $4.26 |
| 52 Week High | $62.75 | $10.08 |
Technical Indicators
Market Signals| Indicator | MLTX | XERS |
|---|---|---|
| Relative Strength Index (RSI) | 45.08 | 50.57 |
| Support Level | $15.37 | $5.76 |
| Resistance Level | $19.16 | $6.41 |
| Average True Range (ATR) | 0.90 | 0.22 |
| MACD | -0.17 | 0.01 |
| Stochastic Oscillator | 9.96 | 41.00 |
Price Performance
Historical ComparisonAbout MLTX MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.